Jennifer A. Woyach, MD, associate professor of hematology at The Ohio State University, spoke with CancerNetwork® about chronic lymphocytic leukemia (CLL) and the current frontline treatment options available for patients with this disease type at the 24th Annual International Congress on Hematologic Malignancies, held from February 27 to March 1, 2020 in Miami, Florida.
CancerNetwork®: What are the frontline options currently for the treatment of CLL?
Woyach: So, for CLL we have a number of frontline options. We have ibrutinib (Imbruvica), which can be used by itself, and usually is used by itself. We have acalabrutinib (Calquence) that can be used with or without obinutuzumab (Imbruvica). And then we have venetoclax (Venclexta) plus obinutuzumab, in terms of our targeted agents. We also still do have chemoimmunotherapy options; FCR, which can be considered especially for…
